Xiaoqin Liu

发表

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

K. Behnia, Rongan Zhang, P. Sleph, 2016, Cell Metabolism.

Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates

P. Sleph, T. Kirchgessner, Richard J Martin, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

P. Sleph, L. Abell, D. Gordon, 2017 .

Potent Triazolopyridine Myeloperoxidase Inhibitors.

P. Sleph, S. Jusuf, L. Abell, 2018, ACS medicinal chemistry letters.

Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression

R. Parker, P. Shipkova, C. Ryan, 2013, Journal of Lipid Research.

Small Molecule and Macrocyclic Pyrazole Derived Inhibitors of Myeloperoxidase (MPO).

S. Jusuf, R. Wexler, J. Smallheer, 2021, Bioorganic & medicinal chemistry letters.

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

P. Sleph, L. Abell, D. Gordon, 2017, MedChemComm.

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis

G. Shearer, M. Budamagunta, J. Genest, 2013, PloS one.

Microsoft Word-5751309-file00.docx

P. Sleph, T. Kirchgessner, G. Cantor, 2014 .

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

Rongan Zhang, P. Sleph, T. Kirchgessner, 2016, Cell metabolism.